Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD123+ Acute Myeloid Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT04230265
What this trial is testing

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)
AvenCell Europe GmbH 32
Early research (Phase 1)Not Yet RecruitingNCT07809906
What this trial is testing

Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

Who this might be right for
CD123+ Acute Myeloid Leukemia
Orum Therapeutics USA, Inc. 42
Very early researchUnknownNCT04156256
What this trial is testing

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03222674
What this trial is testing

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute 10
Early research (Phase 1)Ended earlyNCT03766126
What this trial is testing

Lentivirally Redirected CD123 Autologous T Cells in AML

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, AdultAcute Myeloid Leukemia, Refractory
University of Pennsylvania 22
Testing effectiveness (Phase 2)WithdrawnNCT03739606
What this trial is testing

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Who this might be right for
Acute Biphenotypic LeukemiaAcute LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center
Testing effectiveness (Phase 2)UnknownNCT04265963
What this trial is testing

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Chongqing Precision Biotech Co., Ltd 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Early research (Phase 1)Study completedNCT02715011
What this trial is testing

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC 62
Testing effectiveness (Phase 2)UnknownNCT03556982
What this trial is testing

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

Who this might be right for
Leukemia, Myeloid, Acute
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 10
Early research (Phase 1)Ended earlyNCT04678336
What this trial is testing

CD123 Redirected T Cells for AML in Pediatric Subjects

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, PediatricAcute Myeloid Leukemia, Refractory
University of Pennsylvania 12
Early research (Phase 1)UnknownNCT04014881
What this trial is testing

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

Who this might be right for
CD123+ Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 50
Early research (Phase 1)Study completedNCT02730312
What this trial is testing

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm+1 more
Xencor, Inc. 120
Large-scale testing (Phase 3)UnknownNCT03631576
What this trial is testing

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Who this might be right for
Relapsed/Refractory AML
Fujian Medical University 20
Very early researchNot Yet RecruitingNCT04599543
What this trial is testing

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06561152
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University 20
Early research (Phase 1)Active Not RecruitingNCT02159495
What this trial is testing

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Adult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid Leukemia+10 more
City of Hope Medical Center 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT05673057
What this trial is testing

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyeloidAcute+1 more
Molecular Partners AG 249
Very early researchLooking for participantsNCT06201247
What this trial is testing

Off-the-shelf CD123 CAR-NK for R/R AML

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Peking University People's Hospital 12
Early research (Phase 1)Looking for participantsNCT05949125
What this trial is testing

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
AvenCell Europe GmbH 80
Next Page